CliffBio
small molecule

AZITHROMYCIN

AZITHROMYCIN

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameAZITHROMYCIN
Active ingredientAZITHROMYCIN
StrengthEQ 200MG BASE/5ML
Dosage formFOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2019
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.